Novocure CEO on Fighting Aggressive Cancers, Treatment Development Pipeline

Ashley Cordova, CEO of Novocure (NVCR), joins Trading 360 after ringing the opening bell at the Nasdaq. Novocure “targets the electrical properties of cells” to fight aggressive cancers. “We are focused on extending survival,” she says, and notes recent FDA approval for lung cancer treatment and clinical trials in pancreatic and brain cancers. She also discusses the company’s balance sheet, R&D investment, and potential partnerships.

Trading 360

10 Feb 2025

SHARE

Schwab Network's Newsletters

Daily insights for every investor

ON AIR
8:00 pm
Market Overtime
replay
12:00 am
The Wrap
REPLAY
12:30 am
Market On Close
REPLAY
2:00 am
Trading 360
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
5:00 am
Market Overtime
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Morning Movers
8:00 am
Opening Bell With Nicole Petallides
9:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Fast Market
REPLAY
5:00 pm
Next Gen Investing
REPLAY
6:00 pm
The Wrap
REPLAY
7:30 pm
Market Overtime
REPLAY
ON AIR
8:00 pm
Market Overtime
REPLAY
8:30 pm
Market On Close
REPLAY
10:00 pm
Trading 360
REPLAY
11:00 pm
The Wrap
REPLAY